ARICEPT
LOE ApproachingNDAORALSOLUTION
Approved
Oct 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ARICEPT by Eisai is alzheimer’s disease attribute some of them to a deficiency of cholinergic neurotransmission. Approved for dementia of the alzheimer’s type. First approved in 2004.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARICEPT (donepezil hydrochloride) is an oral acetylcholinesterase inhibitor approved for Alzheimer's disease and related dementias. It works by increasing acetylcholine concentration in the brain to enhance cholinergic neurotransmission, though it does not alter the underlying disease process. The solution formulation enables flexible dosing for patients with swallowing difficulties.
$2MPart D
LOE ApproachingDeclining
Product approaching loss of exclusivity with minimal recent Part D claims signals contraction; teams likely focused on transition planning and generic preparation rather than growth initiatives.
Mechanism of Action
Alzheimer’s disease attribute some of them to a deficiency of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition…
Indications (1)
Clinical Trials (20)
Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).
Started Apr 2015
591 enrolled
Dementia With Lewy Body Disease
A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)
Started Mar 2015
160 enrolled
Dementia, Lewy BodyLewy Body Disease
A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients
Started Mar 2015
2,231 enrolled
Alzheimer's Disease
A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS)
Started Jul 2014
532 enrolled
Alzheimer's Disease
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
Started Jun 2013
8,662 enrolled
Alzheimer's Disease
Worked on ARICEPT at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.